Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

311 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial.
Iijima K, Sako M, Nozu K, Mori R, Tuchida N, Kamei K, Miura K, Aya K, Nakanishi K, Ohtomo Y, Takahashi S, Tanaka R, Kaito H, Nakamura H, Ishikura K, Ito S, Ohashi Y; Rituximab for Childhood-onset Refractory Nephrotic Syndrome (RCRNS) Study Group. Iijima K, et al. Among authors: ishikura k. Lancet. 2014 Oct 4;384(9950):1273-81. doi: 10.1016/S0140-6736(14)60541-9. Epub 2014 Jun 22. Lancet. 2014. PMID: 24965823 Clinical Trial.
Two-year follow-up of a prospective clinical trial of cyclosporine for frequently relapsing nephrotic syndrome in children.
Ishikura K, Yoshikawa N, Nakazato H, Sasaki S, Iijima K, Nakanishi K, Matsuyama T, Ito S, Yata N, Ando T, Honda M; Japanese Study Group of Renal Disease in Children. Ishikura K, et al. Clin J Am Soc Nephrol. 2012 Oct;7(10):1576-83. doi: 10.2215/CJN.00110112. Epub 2012 Jul 26. Clin J Am Soc Nephrol. 2012. PMID: 22837276 Free PMC article. Clinical Trial.
A multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatment.
Yoshikawa N, Nakanishi K, Sako M, Oba MS, Mori R, Ota E, Ishikura K, Hataya H, Honda M, Ito S, Shima Y, Kaito H, Nozu K, Nakamura H, Igarashi T, Ohashi Y, Iijima K; Japanese Study Group of Kidney Disease in Children. Yoshikawa N, et al. Among authors: ishikura k. Kidney Int. 2015 Jan;87(1):225-32. doi: 10.1038/ki.2014.260. Epub 2014 Jul 23. Kidney Int. 2015. PMID: 25054775 Free PMC article. Clinical Trial.
Long-term outcome of childhood-onset complicated nephrotic syndrome after a multicenter, double-blind, randomized, placebo-controlled trial of rituximab.
Kamei K, Ishikura K, Sako M, Aya K, Tanaka R, Nozu K, Kaito H, Nakanishi K, Ohtomo Y, Miura K, Takahashi S, Morimoto T, Kubota W, Ito S, Nakamura H, Iijima K; Rituximab for Childhood-Onset Refractory Nephrotic Syndrome (RCRNS) Study Group. Kamei K, et al. Among authors: ishikura k. Pediatr Nephrol. 2017 Nov;32(11):2071-2078. doi: 10.1007/s00467-017-3718-0. Epub 2017 Jun 29. Pediatr Nephrol. 2017. PMID: 28664242 Clinical Trial.
Study protocol: high-dose mizoribine with prednisolone therapy in short-term relapsing steroid-sensitive nephrotic syndrome to prevent frequent relapse (JSKDC05 trial).
Hama T, Nakanishi K, Ishikura K, Ito S, Nakamura H, Sako M, Saito-Oba M, Nozu K, Shima Y, Iijima K, Yoshikawa N; Japanese Study Group of Kidney Disease in Children (JSKDC). Hama T, et al. Among authors: ishikura k. BMC Nephrol. 2018 Sep 10;19(1):223. doi: 10.1186/s12882-018-1033-z. BMC Nephrol. 2018. PMID: 30200895 Free PMC article. Clinical Trial.
Study protocol: mycophenolate mofetil as maintenance therapy after rituximab treatment for childhood-onset, complicated, frequently-relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicenter double-blind, randomized, placebo-controlled trial (JSKDC07).
Horinouchi T, Sako M, Nakanishi K, Ishikura K, Ito S, Nakamura H, Oba MS, Nozu K, Iijima K. Horinouchi T, et al. Among authors: ishikura k. BMC Nephrol. 2018 Nov 1;19(1):302. doi: 10.1186/s12882-018-1099-7. BMC Nephrol. 2018. PMID: 30382824 Free PMC article. Clinical Trial.
311 results